BioTechLeague Files IPO Prospectus: Powering Global Precision Medicine with End-to-End Digital Solutions for Over 300 Life Science Organizations

It is inaccurate to define BioTechLeague merely as a provider of informatics solutions for smart laboratories. Currently, in addition to delivering informatics solutions to more than 300 smart laboratories worldwide, BioTechLeague’s strategic footprint extends beyond the smart laboratory domain to encompass digital transformation across various segments of the medical industry chain, including biological drug R&D, preclinical studies, and intelligent manufacturing.

For BioTechLeague, which provides enterprises with informatization solutions for production process standardization, quality control, data traceability analysis, and automation, it may be more accurate to describe it as a provider of intelligent management system solutions for life sciences informatization.

BioTechLeague, which has consistently relied on its own capabilities for development, has developed and owns multiple software products with independent intellectual property rights, expanding from the domestic market to the international arena and achieving “snowball”-style growth. At a time when the niche sector of smart laboratories within the life sciences industry is frequently securing financing and attracting attention from top-tier venture capital firms, BioTechLeague’s future expansion strategies may offer valuable insights for emerging companies seeking to establish a presence in the “smart laboratory” sector.

Overview of Financing Status of Selected Companies in the Smart Laboratory Sector, Chart by:“Sequoia and Matrix Partners Make Consecutive Moves, While Hillhouse and ByteDance Enter the Fray: Is This Life Sciences Niche Poised to Explode?”

The decision to enter the smart laboratory sector is closely tied to the background of Ni Yi, founder of BioTechLeague.

Ni Yi, Founder of BioTechLeague

Ni Yi, who grew up in the compound of the Beijing Institute of Biological Products, did not pursue a career in vaccine research and production, but ratherAfter earning a master’s degree from Beihang University and building an academic foundation in computer science, he further specialized in artificial intelligence at the College of Computing at the Illinois Institute of Technology. With over a decade of experience in software development, he has served as project manager and technical director for operational information management systems at multiple large enterprises.

Although not working in the life sciences industry, Ni Yi has maintained his focus on it. In 2010, when the concept of “precision medicine” first emerged, he keenly recognized its connection to digitalization and informatization.

At that time, the informatization of the nuclear power and telecommunications industries had already achieved a certain level of development.However, the level of informatization in China’s life sciences industry remains relatively low—many enterprises are still at the stage of paper-based operations or basic network infrastructure.He noted, “During our visits to U.S. laboratories, we found that the equipment and personnel reserves in Chinese laboratories were not significantly different from those abroad; the key gap lay in management philosophy. At that time, international laboratories had already adopted digital systems to ensure experimental compliance and to effectively implement and uphold their management principles.”

Recognizing that the digital transformation of laboratories is merely a foundational step, Ni Yi decided to devote himself to this field, largely driven by his awareness of the challenges facing the industry.Digitalization in the life sciences sector is now imperative—

“Many patients with advanced-stage tumors derive no pain relief from conventional treatments such as chemotherapy; instead, these therapies often cause further harm to the body. In such cases, precision medicine tailored to the individual patient—including genetic testing, targeted drug screening, and cell and gene therapies—can often yield remarkable results. Throughout this process, patients undergo genetic sequencing at specialized companies to identify therapeutic targets and select appropriate targeted drugs, or provide cells for CAR-T modification followed by reinfusion into the body. These procedures and the associated data must be handled with utmost rigor to prevent any mix-ups. Errors in matching patient information can exact a tremendous cost.”

In fact, during the development of “precision medicine,” the role of laboratory medicine, particularly genetic/molecular diagnostics, has been continuously elevated, leading to increased demand for third-party independent clinical laboratories that require efficient and accurate testing. In this process,Ensuring accurate test results, maintaining testing quality, and controlling testing costs have become major challenges for testing laboratories.

The challenges facing the industry are precisely the problems that digital systems can solve. Recognizing the rising demand for laboratory testing driven by the trend toward “precision medicine,” Ni Yi chose to start with laboratory information management systems (LIMS). His extensive experience in the IT sector made him aware of the critical importance of foundational technology development platforms for industry-specific information systems. Based on this,Since 2010, Ni Yi has led his team in developing the Bio-AP digital system platform—today, all of BioTechLeague’s products operate on this platform.

In 2012, BioTechLeague was established. Joining Ni Yi as a co-founder was Zhu Liwei, who also came from IBM GBS (Global Business Services). Following intensive preparations prior to the company’s inception, BioTechLeague successfully developed its Bio-LIMS 1.0 product in February of the same year. By June, the system gained customer recognition when Biocytogen, a leading innovative drug R&D enterprise in the industry, chose to adopt it.

“‘From the clinic, to the clinic’ is the corporate value and social responsibility that we pursue in founding BioTechLeague,” added Ni Yi. In pursuit of this goal, BioTechLeague has gradually delved deeper into the life sciences sector, evolving from its initial laboratory management system. In addition to its early strategic focus on CROs and precision medicine, BioTechLeague has identified new areas for growth.

Over the past decade, BioTechLeague has launched multiple products.

Its core products include an integrated traceability system for cell and gene therapy data, a laboratory information management system (LIMS) for gene sequencing laboratories, an LIMS for R&D laboratories, a production management system for gene editing, a model animal production system, a biobank management system, a preclinical efficacy testing management system, and an integrated traceability system for vaccine and biological drug production, among others.

The launch of these products has also helped BioTechLeague steadily establish its position in the industry.

To clarify how BioTechLeague has evolved step by step over the past decade to reach its current state,Perhaps two highly significant threads can serve as references:One path is BioTechLeague’s in-depth exploration of the life sciences sector, with a focus on the continuous improvement of its digital infrastructure; the other is the evolution of its market strategy, expanding from a domestic foothold to a global presence and acquiring international clients.

 Overview of BioTechLeague’s Early Development History. Image source: BioTechLeague official website

Specifically, BioTechLeague is currently focused on genomics and biotechnology, providing smart laboratory and intelligent manufacturing informatization solutions to facilitate the digital transformation of life sciences enterprises.

the aforementioned Bio-LIMS Smart Laboratory System, Bio-CELL Cell and Gene Therapy Digitalization System, Bio-Research R&D Laboratory Management System, Bio-Vaccine Biopharmaceutical Production and R&D Management System, Bio-Bank Biobank Management System, Bio-PHRAMA Pharmacodynamic Evaluation Management System, and Bio-Animal Model Animal Management System, among others,Multiple computerized systems have all obtained software copyrights. Several BioTechLeague products have also been awarded the “Beijing New Technology, New Product (Service) Certificate.”Products with independent intellectual property rights are also one of the reasons for BioTechLeague's rapid development.

According to Ni Yi,The evolution of BioTechLeague’s product development strategy has primarily revolved around two factors: one is the emergence and rise of cutting-edge technologies in the pharmaceutical sector, which has driven demand for new informatics solutions; the other is BioTechLeague’s strategic expansion further upstream into the R&D segment, in response to shifts in its clients’ core needs.

For example,In 2016, BioTechLeague recognized the rise of cell therapy technologies and their potential to disrupt traditional treatment modalities.The subsequent emergence of online public opinion incidents, in Ni Yi’s view, further underscores from another perspective the industry’s need for standardized treatment protocols and traceable information. However, traditional pharmaceutical companies’ historical approaches to informatization management are ill-suited for the emerging processes of cell and gene therapies. Based on this insight, in 2016, the BioTechLeague team developed the Bio-CELL V1.0 system, enabling digital management of cell and gene therapies. Today, after multiple upgrades and iterations, the system has evolved to version V5.5, covering cell therapy business lines such as CAR-T, TILs, and CAR-NK.

Ni Yi also mentioned that, inThe Sudden Outbreak of the COVID-19 Epidemic During the 2020 Spring FestivalIt disrupted people’s daily lives and work routines, leading to repeated extensions of the Spring Festival holiday. Ni Yi also organized BioTechLeague team members to work from home and launched a cloud-based COVID-19 Bio-LIMS testing system, which was offered free of charge to nucleic acid testing companies responding to the pandemic. In March 2020, this system participated in the “Maker Beijing 2020” Epidemic Special Competition and advanced into the top 50.

For another example, in 2020, BioTechLeague designed and developed the Bio-Research system, which was also based on the results of its communication with a wide range of laboratory customers. They found that,Clients are gradually shifting their focus to the pre-tech-transfer R&D phase. Bio-Research streamlines the management of biologics development processes, serving as a critical foundation for subsequent tech transfer.The system supports the entire R&D processes for genetic testing, cell therapy, biologics, and antibody drugs.

In response to the “2022 Informatics Challenge” facing the vaccine and other biologics manufacturing industries, Ni Yi identified that one of the industry’s pain points was the “heaviness” of systems and their lengthy implementation cycles, and thus proposedDevelop a digital production system for biologics, such as the “compact, agile, and flexible” Bio-Vaccine. Compared with traditional large-scale MES and LIMS systems, it enables rapid deployment, helping enterprises accelerate their digital transformation and upgrading.

“Since 2012, I have collaborated with life science CRO and CDMO companies. My initial exposure to CRO services included animal colony management, model organisms, and gene knockout technologies. Later, I engaged with CDMO services such as antibody drug development, cell culture, and vaccine production. I observed that their core characteristic is providing services to clients. To effectively manage clients and projects, key areas of focus include configurable production workflows, finished goods management, cost and revenue management, and a comprehensive permission system. Based on these insights, BioTechLeague developed a production workflow management system tailored for CDMO companies,” added Ni Yi.

BioTechLeague Industry and Product Portfolio Map

For BioTechLeague, another relatively subtle development trajectory lies in leveraging its expansion into international markets to fuel the digital transformation of China’s life sciences industry.

This line of development began in 2016.

In 2016, Ni Yi established Bio LIM Inc. in the United States and launched the international version of the Bio-LIMS system, initiating efforts to globalize its digital solutions.Behind this endeavor lies BioTechLeague’s insight into the pain points hindering the development of U.S. laboratories. Ni Yi and his team previously visited multiple laboratories in the United States, including Dana-Farber and Baylor. They found that although these laboratories had adopted relevant digital systems, they still faced significant challenges. Not only Chinese scientists’ laboratories, but also local U.S. laboratories have shown strong interest in such digital solutions.

BioTechLeague leverages best practices established in international laboratories to further enhance the digital systems of domestic laboratories. It is worth noting that there is a gap between international and Chinese laboratories in their acceptance of cloud computing concepts. This distinction has also prompted BioTechLeague to rethink its approach to new product development.

2018 was regarded as a landmark year for BioTechLeague’s international expansion.Following a visit to the National Genomics Programme laboratory in Ireland, BioTechLeague’s Bio-LIMS International system was launched and deployed at WuXi NextCode’s laboratory in the United States. This marks a new step forward for BioTechLeague in the international market.

In 2020, BioTechLeague further entered into a partnership with Predicine, an international high-tech group headquartered in the United States and specializing in precision medicine, with a research focus on the molecular mechanisms of cancer. Based on the Bio-LIMS V7.6 International Edition, BioTechLeague provided Predicine with a LIMS system that met the requirements for building intelligent production-line laboratories in compliance with international standards, thereby achieving comprehensive informatization management of Predicine’s overall business operations.

A more typical example isIn 2020, a national-level genomics program laboratory in the Middle East adopted and implemented the Bio-LIMS system.In this laboratory, the BioTechLeague team served laboratory personnel from China, the United States, the Middle East, Europe, and other regions. They addressed diverse integration requirements involving instrumentation manufacturers from China and the United States, as well as software systems from Europe. Ultimately, the Bio-LIMS system was successfully launched and became the core system of the laboratory.

Currently, BioTechLeague’s footprint spans across Asia, the Americas, and Europe, with its systems successfully implemented in multiple countries.When hardware manufacturers integrating BioTechLeague’s information management applications are included, its product footprint spans every continent worldwide.

Expanding into overseas markets is not without its challenges. Ni Yi noted that cultural differences across countries mean that integrating medical devices and information systems globally requires addressing not only language barriers but also cultural nuances. Furthermore, system usage must accommodate the habits of overseas users. These factors place high demands on the flexibility of system configuration.

The adoption of BioTechLeague’s Bio-LIMS system by COVID-19 laboratories in the United States and a national-level genomics program laboratory in the Middle East,Its widespread global adoption is also attributable to the team at BioTechLeague and their strong commitment to service.

BioTechLeague boasts a team of technically skilled professionals with extensive business experience, as well as a core team of foreign experts responsible for international operations.Currently, the company has assembled a talent team with expertise in IT, AI, IoT, GMP, and other related fields. Among them are professionals with nearly two decades of experience in the digitalization of scientific research management systems. Some team members also bring relevant professional backgrounds, including former IBM information systems consultants, experts in the biopharmaceutical industry, and specialists from the Center for Drug Evaluation (CDE). Ni Yi, currently serving as the company’s Chairman and Chief Technology Officer, is primarily responsible for corporate strategy and exploring product and technological directions. Zhu Liwei, formerly of IBM Global Business Services (GBS), oversees the company’s operations.

Bio-LIMS International Edition System Modules

At BioTechLeague, the philosophy is that “There is no best LIMS, but suitable LIMS.” The relationship with suppliers is also defined as a “partnership rather than vendor-client ship.”Not only does BioTechLeague provide system products, but it also delivers product services to customers, which has earned the company a better reputation overseas.

Ni Yi also mentioned that it was precisely by relying on R&D and innovation, as well as the implementation of the “product + service” philosophy, that BioTechLeague achieved rapid development over the past decade.

Behind the development of the life sciences industry lies Ni Yi’s understanding of the digital transformation of life sciences enterprises.

In his view, the industry-standard approach to advancing digitalization in the life sciences sector comprises several stages: 1. Paper-based operations; 2. Informatization; 3. Integration; 4. Automation; and 5. Intelligence. Currently, BioTechLeague focuses primarily on stages 3, 4, and 5—enabling process execution without manual intervention and leveraging scientific decision-making based on big data, machine learning, and deep learning to further optimize processes.

BioTechLeague, deeply rooted in the life sciences industry,Digital systems now cover every link in the pharmaceutical industry, from research to clinical practice and from R&D to manufacturing. For Ni Yi, BioTechLeague’s future goals are clear: to focus on informatics for genetics and biotechnology, realize smart laboratories and intelligent manufacturing, facilitate the digital transformation of biopharmaceutical enterprises, and empower innovation in biological drugs through digitalization.

To achieve this goal, BioTechLeague is also advancing the application of artificial intelligence, GxP digitalization, IIoT (Industrial Internet of Things), and cloud technologies within the life sciences industry. “What we are doing is driving cloud-based services and intelligent solutions. We will fully leverage the advantages of cloud services to meet both the need for rapid, flexible usage and compliance requirements. Meanwhile, we are conducting in-depth research into technologies such as machine learning and deep learning, integrating these new innovations into our BioAP technology platform.” Currently, BioTechLeague is collaborating closely with cloud computing providers to develop integrated solutions.

At the industry conference, Ni Yi shared “Practices and Prospects of Digital Transformation in Life Sciences Enterprises”

Over the past decade, BioTechLeague has focused on precision medicine, biopharmaceutical R&D and manufacturing, cell and gene therapy, CRO, and CDMO. The company has established collaborations with leading hospitals and research institutions, including Peking Union Medical College Hospital, Chinese PLA General Hospital, Peking University Cancer Hospital, Fuwai Hospital of the Chinese Academy of Medical Sciences, Fudan University Shanghai Cancer Center, and the Chinese Academy of Sciences. It has also partnered with enterprises such as Shanghai Pharmaceuticals, Biocytogen, WuXi AppTec, Genetron Health, and VisionGene.

In the future, BioTechLeague will further ensure compliance and enhance value in the life sciences industry through the application of digital systems.“Our focus extends beyond smart laboratories; we aim to evolve from Bio-LIMS into Bio-TechLeague, and further advance toward intelligent manufacturing.”Ni Yi said confidently.